Searched for
ONCOLOGY FOCUSED BIOSIMILARS
Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potential
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technology
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...27 Jul, 2026, 12.52 PM IST
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...03 Jul, 2026, 12.49 PM IST
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...07 Apr, 2026, 07.44 PM IST
- Alkem launches breast cancer biosimilar in IndiaAlkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously d...22 Sep, 2025, 08.03 PM IST
- Aurobindo Pharma shares in focus after European Commission nod for cancer drug DazublysAurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, Dazublys, indicated ...03 Jul, 2025, 09.18 AM IST
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...06 Jun, 2025, 10.55 AM IST
- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...06 Jun, 2025, 09.33 AM IST
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...05 Jun, 2025, 01.01 PM IST
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...10 May, 2025, 08.31 PM IST
- Dr Reddy's unit ties up with Shanghai Henlius BiotechDr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Dar...06 Feb, 2025, 04.35 PM IST
- Biocon plans IPO for biosimilars business by March 2026Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars l...01 Feb, 2025, 08.53 AM IST
- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...06 Jan, 2025, 11.51 PM IST
- Lupin announces USFDA acceptance for a biosimilar applicationThe pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...02 Jun, 2021, 05.32 PM IST
- Top cancer drugs may come under price controlTaking cue from the WHO’s revised list of essential medicines, popular biosimilars for cancer cure may get incorporated in India’s revised ...07 Jan, 2020, 01.03 PM IST
- Aurobindo Pharma to launch oncology, respiratory products in US by 2021The company is also focussing on securing intellectual property (IP) and ramping up and filing of specialty products.18 Nov, 2018, 10.58 AM IST
- USFDA accepts Mylan's BLA for proposed biosimilar PegfilgrastimThe proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...17 Feb, 2017, 04.12 PM IST
- US FDA accepts Biocon-Mylan biosimilar application for proposed anti-cancer bio-similarBiocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...16 Feb, 2017, 08.28 PM IST
Load More
